Fig. 4
From: Advances of radiolabeled GRPR ligands for PET/CT imaging of cancers
Comparison of 99mTc-MDP bone scintigraphy (A), 68Ga-RM26 PET/CT (B), and 68Ga-BBN PET/CT (C) in a 73-y-old man diagnosed as having PC (white arrow) with lymph node involvement (red arrow) and bone metastasis (yellow arrow) before prostatectomy. 68Ga-RM26 PET/CT detected primary tumors, multiple lymph node involvement, and bone metastasis lesion, whereas those lesions did not significantly show up on 99mTc-MDP bone scintigraphy and showed extremely mild uptake on 68 Ga-BBN PET/CT. This study was originally published in JNM. Zhang, J., et al., PET Using a GRPR Antagonist (68)Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients. J Nucl Med, 2018. 59(6): p. 922–928. © SNMMI